Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
VR and imaging advancements showcased at AAO 2025 | Ophthalmology Times
Image credit: AdobeStock/Kittiphat The annual American Academy of Ophthalmology (AAO) meeting offered an opportunity for the ophthalmic industry to showcase their latest technologies designed to benefit patients and simplify the processes in an ophthalmology practice. Among the many products and…
What if? Ophthalmology without OCT – Part 2 | Ophthalmology Times
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented. Video Transcript: Editor’s note: The below…
Throwback Series: Managing childhood glaucoma in a resource-limited locale | Ophthalmology Times
In celebration of Ophthalmology Times’ 50th anniversary, leaders revisit a memorable “throwback” case from earlier in their careers. In this special series, they reflect on how evolving knowledge, techniques, and technologies have transformed the way such cases are managed today.…
Research supports that iron dysregulation may drive AMD | Ophthalmology Times
Image credit: AdobeStock/Gorodenkoff A new study supports the hypothesis that iron dysregulation may be a driver of dry age-related macular degeneration (AMD). This could be especially true in the early stage of geographic atrophy (GA). According to the research, the…
ONL Therapeutics randomizes first patient in phase 2 GALAXY trial evaluating xelafaslatide | Ophthalmology Times
(Image Credit: AdobeStock/Kirsten D) ONL Therapeutics announced the first patient has been randomized in its phase 2 GALAXY (NCT06659445) trial evaluating xelafaslatide (formerly ONL1204) in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). According to the…
Advancements in femtosecond laser technology benefit surgeons and patients | Ophthalmology Times
(Image Credit: AdobeStock/Wirestock) The field of refractive surgery has undergone multiple technological developments aimed at enhancing patient outcomes, optimizing workflows, and improving patient satisfaction. The VisuMax laser platform (Zeiss) is among the commercially available femtosecond laser systems and is used…
Bimatoprost drug pad-IOL system shows reduction in mean IOP at 24 months | Ophthalmology Times
Image credit: AdobeStock/oz Interim 24-month data from a trial of the bimatoprost drug pad-IOL system (BIM-IOL system) showed sustained improvements in intraocular pressure (IOP) and visual acuity outcomes.1 The BIM-IOL system has been developed by SpyGlass Pharma, Inc. The company…
What if? Ophthalmology without OCT – Part 1 | Ophthalmology Times
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented. Video Transcript: Editor’s note: The below…
Porter Ophthalmology Clarifies Long-Term Vision Planning for LASIK Patients Considering Cataract Surgery
Raleigh, NC – October 27, 2025 – PRESSADVANTAGE – With millions of Americans having undergone LASIK vision correction in the past three decades, a growing number are now approaching the age where cataract surgery becomes a consideration. Porter Ophthalmology, a…
Q&A: William F. Wiley, MD, on what BVI’s trifocal IOL approval means for US premium vision options | Ophthalmology Times
The FDA’s approval of the FineVision HP trifocal lens expands the range of premium lens option to US ophthalmologists and their patients. (Image credit: AdobeStock/Margarita Ratatosk) As the landscape of ophthalmic innovation continues to evolve, new technologies are reshaping how…